NONALCOHOLIC STEATOHEPATITIS (NASH)
Clinical trials for NONALCOHOLIC STEATOHEPATITIS (NASH) explained in plain language.
Never miss a new study
Get alerted when new NONALCOHOLIC STEATOHEPATITIS (NASH) trials appear
Sign up with your email to follow new studies for NONALCOHOLIC STEATOHEPATITIS (NASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
First human test for promising fatty liver drug begins
Disease control Recruiting nowThis early-stage study is testing whether a new drug called miricorilant can reduce fat buildup in the liver of people with MASH, a serious form of fatty liver disease. Eight participants will take the drug daily for six weeks while researchers measure changes in liver fat produc…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE1 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New drug trial targets dangerous liver fat
Disease control Recruiting nowThis study is testing whether an investigational drug called ADI-PEG 20 can safely reduce the amount of fat in the liver of people with NASH, a serious form of fatty liver disease. About 60 adults with confirmed NASH will receive either the drug or a placebo for 24 weeks. The mai…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE2 • Sponsor: Polaris Group • Aim: Disease control
Last updated Mar 16, 2026 15:27 UTC